Radiation reduces carboplatin sensitivity and enhances nedaplatin sensitivity in cervical squamous cell carcinoma in vitro

Background: The study was performed to examine how the platinum anticancer drugs other than cisplatin, such as carboplatin (CBDCA) and nedaplatin (NEP) can be effectively used in chemoradiotherapy for cervical squamous cell carcinoma patients.

Materials and methods: The radiosensitive human cervical squamous cell carcinoma cell line ME180 was examined to investigate the radiation effects on CBDCA and NEP sensitivities of the cells.

Results: Irradiation significantly reduced cellular CBDCA sensitivity. There were no significant changes in CBDCA sensitivity between the cells concurrently irradiated and those treated with CBDCA 8 h before or 8 h after irradiation. However NEP sensitivity of the cells treated 8 h before or 8 h after irradiation was significantly higher than that in cells concurrently irradiated.

Conclusions: Although CBDCA sensitivity in the concurrently irradiated cells is reduced, NEP sensitivity is enhanced by irradiation. NEP, but not CBDCA, therefore, may be a candidate anticancer drug for concurrent chemoradiotherapy for cervical cancer. For the greatest efficacy, NEP should be administered to patients several hours before or after irradiation.

Carboplatin; Cervical cancer; Chemoradiotherapy; Nedaplatin; Squamous cell carcinoma

[1] Morris M., Eiufel P.J., Lu J., Grigsby P.W. et al.: "Pelvic radiaiton with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer". New Engl. J. Med., 1999, 340, 1137.

[2] Rose P.G., Bundy B.N., Watkins E.B. et al.: "Concurrent c1splatin-based radiotherapy and chemotherapy for locally advanced cervical cancer". New Engl. J. Med., I 999, 340, 1144.

[3] W hitney C.W., Sause W., Bundy B.N. et al.: "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiaiton therapy in Stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncoloy Group and Southeast On cology Group Study". J. Clin. Oneal., 1999, 17, 1339.

[4] Keys H.M., Bundy B.N., Stehman F.B. et al.: "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage TB cervical carcinoma". New Eng J. Med., 1999, 340, 1154.

[5] Peters W.A. 3nd Liu P. Y., Barrett R.J. 2"' et al.: "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix". J. Clin. Oneal., 2000, 18, 1606.

[6] Roberts K.B., Urdaneta N., Vera R. et al.: "lnterim results of a randomized trial of mitomyocin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-celle carcinoma of the cervix". Int. J. Cancer, 2000, 90, 206.

[7] Lorvidhaya V., Chitapanarux I., Sangruchi S. et al.: "Concurrent mitomycin C, 5-tluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial". Int. J. Radiat. Oncol. Biol. Phys., 2004, 55, 1226.

[8] Eifel P.J., Winter K., Morris M. et al.: "Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01". J. Clin. Oncol., 2004, 22, 872.

[9] Arseneau J., Blessing J.A., Stehman F.B. et al.: "A phase II study of carboplatin in advanced squamous cell carcinoma of the cervix (a Gynecologic Oncology Group Study)". Invest. New Drugs, 1986,4,187.

[10] Weiss G.R., Green S., Hannigan E.Y. et al.: "A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group Study". Gynecol Oneal., 1990, 39, 332.

[11] YamamotoK.,Iwahana M., Kumazawa E. et al.: "Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines". Oneal. Rep., 2003, 10, 593.

[12] Machida S., Ohwada M., Fujiwara H. et al.: "Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer". Oncology, 2003, 65, 102.

[13] Tsuda H., Hashiguchi Y., Nishimura S., et al.: "Phase I-II study of irinotecan (CPT-!!) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer". Br. J. Cancer, 2004, 91, 1032.

[14] Corn B.W., Hernandez E., Anderson L., et al.: "Phase I/II study of concomitant irradiation and carboplatin for locally advanced carcinoma of the uterine cervix: an interim report". Am. J. Clin Oncol., 1996, 19, 317.

[15] Duenas-Gonzales A., Cetina L., Sanchez B. et al.: "A phase I study of carboplatin concurrent with radiation in F IGO Stage IIIB cervix uteri carcinoma". Int. J. Radiat. Oncol. Biol. Phys., 2003, 56, 1361.

[16] Corn B.W., Micaily B., Dunton C.J., et al.: "Concomitant irradiation and dose-escalating carboplatin for locally advanced carcinoma of the uterine cervix: an updated report". Am. J. Clin Oncol., 1998, 21, 31.

[17] Idei T., Sakamoto H., Nakajima Y. et al.: "Concurrent weekly nedaplatin-based radiotherapy for high risk, recurrent and advanced cervical cancer". Gan To Kagaku Ryoho,2 003,3 0,S OS.

[18] Hatae M.,Ta kahashi T.,K odama S. et al.: "A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer". Tan To Kagaku Ryoho, 2005, 32, 473.

[19] Tanaka T., Yukawa K., Umesaki N.: "Radiation enhances cisplatinsensitivity in human cervical squamous cancer cells in vitro". Eur. J. Gynaecol. Oncol., 200S, 26, 431.

[20] Lancillotti F., Giandomenico Y., Affabris E. et al.: "Interferon alpha-2b and retinoic acid combined treatment affects proliferation and gene expression of human cervical carcinoma cells". Cancer Res., 1995, 55, 3158.

[21] Tanaka T., Bai T., Yukawa K. et al.: "Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells". Oncol. Rep., 2005, 14, 941.